Physician profile
Amanda N Wright
NPI 1891082749
$4,364.69
in general payments reported to CMS, 2019-2025
33 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $649 · 2020: $252 · 2021: $46.70 · 2022: $429 · 2023: $491 · 2024: $572 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Travel and Lodging: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.75 |
| Travel and Lodging | $1,283.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,687.54 | 2019-2025 | |
| Abbvie INC. | $384.01 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $361.30 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $297.75 | 2019-2024 | Ozempic, Rybelsus |
| Allergan, INC. | $237.59 | 2019-2020 | |
| Amgen INC. | $193.43 | 2019-2025 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals Lp | $187.58 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Medtronic, INC. | $101.39 | 2022 | |
| Esperion Therapeutics, INC. | $84.66 | 2024-2025 | Nexletol |
| Nevro Corp. | $70.73 | 2019 | |
| Idorsia Pharmaceuticals US INC | $66.65 | 2022-2023 | Quviviq |
| Biosense Webster, INC. | $61.55 | 2022 | |
| Axsome Therapeutics, INC. | $60.58 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.30 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $50.75 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $49.95 | 2023-2024 | Edarbi, Horizant |
| Glaxosmithkline, LLC. | $42.01 | 2023-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $40.07 | 2022-2024 | Trintellix |
| Astellas Pharma US INC | $38.80 | 2023 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $31.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.67 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.28 | 2022 | |
| Ascendis Pharma Endocrinology INC | $25.51 | 2025 | Yorvipath |
| Lexicon Pharmaceuticals, INC. | $24.36 | 2024 | |
| Corcept Therapeutics | $22.96 | 2023 | Korlym |
| Pfizer INC. | $19.24 | 2024 | |
| Dexcom, INC. | $18.92 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $18.81 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.42 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $16.42 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.39 | 2023 | Livalo |
| Arbor Pharmaceuticals, INC. | $13.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.